Clinical Trial Update: To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of SCD-044 in moderate-to-severe atopic dermatitis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• SCD-044

Snippet

Sponsor: Sun Pharmaceutical Industries Limited | Conditions: Dermatitis, Atopic | Phase 2 | Status: COMPLETED | Results posted: 2025-12-30